PURPOSE: Little is known about the potential carcinogenicity of the triazinone herbicide metribuzin. We evaluated the association between metribuzin use and cancer risk in the Agricultural Health Study, a prospective cohort study of licensed pesticide applicators in Iowa and North Carolina. METHODS: Applicators (N=23,072) provided information on metribuzin use on a self-administered questionnaire at enrollment (1993-1997). Among metribuzin users (n=8,504), there were 554 incident cancer cases. We used multivariable Poisson regression to evaluate potential associations between metribuzin use and cancer incidence by using two quantitative exposure metrics, lifetime days and intensity-weighted lifetime days. RESULTS: Using intensity-weighted lifetime days, the rate ratio (RR) and 95% confidence interval (CI) for the highest exposed tertile for lymphohematopoietic malignancies were 2.09 (95% CI: 0.99-4.29), p trend=0.02 and 2.42 (95% CI: 0.82-7.19), p trend=0.08 for leukemia. For non-Hodgkin lymphoma, the RR was 2.64 (95% CI: 0.76-9.11), p trend=0.13 for lifetime days and 2.52 (95% CI: 0.66-9.59), p trend=0.13 for intensity-weighted lifetime days. Patterns of association were similar for both exposure metrics, but associations were generally weaker than for intensity-weighted days. CONCLUSIONS: The results from this study suggest a potential association between metribuzin use and certain lymphohematopoietic malignancies; however, having not been observed previously, caution should be used in interpretation.
PURPOSE: Little is known about the potential carcinogenicity of the triazinone herbicide metribuzin. We evaluated the association between metribuzin use and cancer risk in the Agricultural Health Study, a prospective cohort study of licensed pesticide applicators in Iowa and North Carolina. METHODS: Applicators (N=23,072) provided information on metribuzin use on a self-administered questionnaire at enrollment (1993-1997). Among metribuzin users (n=8,504), there were 554 incident cancer cases. We used multivariable Poisson regression to evaluate potential associations between metribuzin use and cancer incidence by using two quantitative exposure metrics, lifetime days and intensity-weighted lifetime days. RESULTS: Using intensity-weighted lifetime days, the rate ratio (RR) and 95% confidence interval (CI) for the highest exposed tertile for lymphohematopoietic malignancies were 2.09 (95% CI: 0.99-4.29), p trend=0.02 and 2.42 (95% CI: 0.82-7.19), p trend=0.08 for leukemia. For non-Hodgkin lymphoma, the RR was 2.64 (95% CI: 0.76-9.11), p trend=0.13 for lifetime days and 2.52 (95% CI: 0.66-9.59), p trend=0.13 for intensity-weighted lifetime days. Patterns of association were similar for both exposure metrics, but associations were generally weaker than for intensity-weighted days. CONCLUSIONS: The results from this study suggest a potential association between metribuzin use and certain lymphohematopoietic malignancies; however, having not been observed previously, caution should be used in interpretation.
Authors: Joseph Coble; Jane A Hoppin; Lawrence Engel; Omur Cinar Elci; Mustafa Dosemeci; Charles F Lynch; Michael Alavanja Journal: J Expo Anal Environ Epidemiol Date: 2002-11
Authors: Mustafa Dosemeci; Michael C R Alavanja; Andrew S Rowland; David Mage; Shelia Hoar Zahm; Nathaniel Rothman; Jay H Lubin; Jane A Hoppin; Dale P Sandler; Aaron Blair Journal: Ann Occup Hyg Date: 2002-03
Authors: A J De Roos; S H Zahm; K P Cantor; D D Weisenburger; F F Holmes; L F Burmeister; A Blair Journal: Occup Environ Med Date: 2003-09 Impact factor: 4.402
Authors: W J Lee; J S Colt; E F Heineman; R McComb; D D Weisenburger; W Lijinsky; M H Ward Journal: Occup Environ Med Date: 2005-11 Impact factor: 4.402
Authors: Saúl Flores-Maya; Sandra Gómez-Arroyo; María Elena Calderón-Segura; Rafael Villalobos-Pietrini; Stefan M Waliszewski; Leticia Gómez de la Cruz Journal: Toxicol In Vitro Date: 2005-03 Impact factor: 3.500
Authors: Sara Karami; Gabriella Andreotti; Stella Koutros; Kathryn Hughes Barry; Lee E Moore; Summer Han; Jane A Hoppin; Dale P Sandler; Jay H Lubin; Laurie A Burdette; Jeffrey Yuenger; Meredith Yeager; Laura E Beane Freeman; Aaron Blair; Michael C R Alavanja Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-07-05 Impact factor: 4.254
Authors: Dominik D Alexander; Douglas L Weed; Pamela J Mink; Meghan E Mitchell Journal: Int Arch Occup Environ Health Date: 2011-12-10 Impact factor: 3.015
Authors: A Blair; C J Hines; K W Thomas; M C R Alavanja; L E Beane Freeman; J A Hoppin; F Kamel; C F Lynch; J H Lubin; D T Silverman; E Whelan; S H Zahm; D P Sandler Journal: Am J Ind Med Date: 2015-02 Impact factor: 2.214
Authors: Eryn K Matich; Jonathan A Laryea; Kathryn A Seely; Shelbie Stahr; L Joseph Su; Ping-Ching Hsu Journal: Ecotoxicol Environ Saf Date: 2021-05-21 Impact factor: 7.129